Ceftriaxone is twice as cost-effective as standard therapy in biliary tract infection

Hepato-Gastroenterology

Volumn 51, Issue 58, 2004, Pages 941-945

  Zoepf, Thomas ^a,b   Jakobs, Ralf ^a   Riemann, Juergen F ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Biliary tract infection; Ceftriaxone; Cephalosporins; Cost effectiveness analysis; Matched pair analysis

Indexed keywords

AMINOPENICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CEFOTIAM; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; PENICILLIN G;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BILIARY TRACT INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMASES; BILIARY TRACT DISEASES; CEFTRIAXONE; CEPHALOSPORINS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLINS; PROSPECTIVE STUDIES;

EID: 3042515555     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Maikowski C, Rosch W, Sörgel F: Ceftriaxon beim malignen Verschlußikterus. Untersuchungen zur Serum- und Gallenkonzentration bei gestörter Gallenausscheidung. Fortschr Med 1993, 111:513-516.
2. Birkner B, Adam D, Kaess H: Elimination von 1g Ceftriaxon i.v. in die Galle bei mechanischem Verschlußikterus. ZAC 1989, 7:103-107.
3. Van Delden OM, Jan Leeuwn DJ, Jansen PL, et al: Biliary excretion of ceftriaxone into non stagnant and stagnant bile. J Antimicrob Chemother 1994; 33:193-194.
4. Leung JW, Chan RC, Cheung SW, et al: The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime. J Antimicrob Chemother 1994; 25:399-406.
5. Van den Hazel SJ, De Vries XH, Speelman P, et al: Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. Antimicrob Agents Chemother 1996; 40:2658-2660.
6. Leung JW, Ling TK, Chan RC, et al: Antibiotics, biliary sepsis and bile duct stones. Gastrointest Endosc 1994; 40:716-721.
7. Hanau LH, Steigbigel NH: Cholangitis: pathogenesis, diagnosis and treatment. Curr Clin Top Infect Dis 1995; 15:153-178.
8. Westphal JF, Brogard JM: Biliary tract infections. A guide to drug treatment. Drugs 1999; 57:81-91.
9. Thompson J, Bennion RS, Pitt HA: An analysis of infectious failures in acute cholangitis. HPB Surg 1994; 8:139-145.
10. Gerecht WB, Henry NK, Hoffmann WW, et al: Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med 1989; 149:1279-1284.
11. Muller LE, Pitt HA, Thompson JE, et al: Antibiotics in infections of the biliary tract. Surg Gynecol Obstet 1987; 165:285-292.
12. Thompson JE, Pitt HA, Doty JE, et al: Broad spectrum penicillin as an adequate therapy for acute cholangitis. Surg Gynecol Obstet 1990; 171:275-282.
13. Bergeron MG, Mendelson J, Harding GK, et al: Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections. Antimicrob Agents Chemother 1988; 32:1231-1236.
14. Owens NJ, Nightingale CH, Quintiliani R, et al: Concentrations of ceftriaxone in gallbladder wall, bile, and serum in patients undergoing cholecystectomy. Clin Pharm 1987; 6:967-968.
15. Brogard JM, Blickle JF, Jehl F, et al: High biliary elimination of ceftriaxone in man. Int J Clin Pharm Ther Toxicol 1988; 26:167-172.
16. Becker HP, Adam D, Hartel W: Einmalgabe von Ceftriaxon zur Prophylaxe in der Gallenwegschirurgie. Klinische Ergebnisse und Konzentrationsbestimmungen nach Applikation von 1g. ZAC 1988; 6:121-125.
17. Orda R, Berger SA, Levy Y, et al: Penetration of ceftriaxone and cefoperazone into bile and gallbladder tissue in patients with acute cholecystitis. Dig Dis Sci 1992; 37:1691-1693.
18. Gastinger I, Lippert H, Brandt U, et al: Notwendigkeit einer Antibiotikaprophylaxe bei laparoskopischer und konventioneller Cholezystektomie. Resultate einer prospektiven Qualitätssicherungsstudie über 4477 Cholezystektomien. MIC 1996; 5:143-149.
19. Richards DM, Hard RC, Brogden RN, et al: Ceftriaxone, a review of ist antibacterial activity, pharmacological properties and therapeutic use. Drugs 1984; 24:469-527.
20. Szucs TD, Schramm W: [Economic evaluation of medical therapy - methodological principles]. Zentralbl Chir 1995; 120:577-583.
21. Woolson RF, McNutt LA: Analysis of matched samples. Infect Control Hosp Epidemiol 1989 Mar; 10:123-126.
22. Benson K, Hartz AJ: A Comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878-1886.